1. Search Result
Search Result
Results for "

tandem

" in MedChemExpress (MCE) Product Catalog:

20

Inhibitors & Agonists

1

Screening Libraries

1

Peptides

1

Inhibitory Antibodies

2

Natural
Products

1

Recombinant Proteins

1

Isotope-Labeled Compounds

1

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-141539

    Histone Methyltransferase Cancer
    SETDB1-TTD-IN-1 is a potent, selective and endogenous binder competitive ligand of SET domain bifurcated protein 1 tandem tudor domain (SETDB1-TTD) that binds to TTD, with a Kd of 88 nM. SETDB1-TTD-IN-1 increases SETDB1 methyltransferase activity. SETDB1-TTD-IN-1 can be used for the research of biological functions and disease associations of SETDB1-TTD .
    SETDB1-TTD-IN-1
  • HY-113005

    Endogenous Metabolite Metabolic Disease
    Glutarylcarnitine is the diagnostic metabolite for malonic aciduria and glutaric aciduria type I monitored in most tandem mass spectrometry newborn screening programmes.
    Glutarylcarnitine
  • HY-113005A

    Endogenous Metabolite Metabolic Disease
    Glutarylcarnitine lithium is the diagnostic metabolite for malonic aciduria and glutaric aciduria type I monitored in most tandem mass spectrometry newborn screening programmes .
    Glutarylcarnitine lithium
  • HY-113005S

    Isotope-Labeled Compounds Endogenous Metabolite Metabolic Disease
    Glutarylcarnitine-d9 (chloride) is the deuterium labeled Glutarylcarnitine chloride. Glutarylcarnitine is the diagnostic metabolite for malonic aciduria and glutaric aciduria type I monitored in most tandem mass spectrometry newborn screening programmes.
    Glutarylcarnitine-d9 chloride
  • HY-141539A

    Histone Methyltransferase Cancer
    SETDB1-TTD-IN-1 TFA is a potent, selective and endogenous binder competitive ligand of SET domain bifurcated protein 1 tandem tudor domain (SETDB1-TTD) that binds to TTD, with a Kd of 88 nM. SETDB1-TTD-IN-1 TFA increases SETDB1 methyltransferase activity. SETDB1-TTD-IN-1 TFA can be used for the research of biological functions and disease associations of SETDB1-TTD .
    SETDB1-TTD-IN-1 TFA
  • HY-114323

    PROTACs FLT3 Apoptosis Cancer
    PROTAC FLT-3 degrader 1 is a von Hippel-Lindau-based PROTAC FLT-3 internal tandem duplication (ITD) degrader with an IC50 0.6 nM. Anti-proliferative activity; apoptosis induction .
    PROTAC FLT-3 degrader 1
  • HY-110026

    FLT3 Cancer
    GTP-14564 is a tyrosine kinase inhibitor targeting to internal tandem duplication (ITD) and FLT3. GTP-14564 inhibits FLT3 ligand-dependent growth in Ba/F3 leukemia cells .
    GTP-14564
  • HY-139064

    Potassium Channel Neurological Disease Inflammation/Immunology
    NPBA, a potassium K2P channel TASK-3 (KCNK9) agonist, is a tandem pore domain weak inward rectifying K + channel (TWIK2) channel blocker. NPBA suppresses NLRP3 inflammasome activation in macrophages .
    NPBA
  • HY-125831

    Biochemical Assay Reagents Others
    ITIC-4F is an indacenodithienothiophene (IDTT)-based postfullerene electron acceptor. ITIC-4F has broad applicability in high-efficiency binary and ternary single-junction as well as tandem polymer solar cells (PSCs) .
    ITIC-4F
  • HY-125292

    Histone Methyltransferase Ligands for E3 Ligase Cancer
    NV03 is a potent and selective antagonist of UHRF1 (Ubiquitin-like with PHD and RING finger domains 1)- H3K9me3 interaction by binding to UHRF1 tandem tudor domain, with a Kd of 2.4 μM. NV03 has anticancer activity .
    NV03
  • HY-146680

    FLT3 RET CDK MAP4K Cancer
    FLT3/ITD-IN-4 (Compound 16) is a selective FMS-like tyrosine kinase 3 internal tandem duplications (FLT3-ITD) inhibitor with an IC50 of 2.3 nM. FLT3/ITD-IN-4 can be used for acute myeloid leukemia research .
    FLT3/ITD-IN-4
  • HY-126020
    Bractoppin
    2 Publications Verification

    DNA/RNA Synthesis RAD51 Cancer
    Bractoppin is a potent and selective agent-like inhibitor of phosphopeptide recognition by the human BRCA1 tandem(t) BRCT domain (binding IC50: 74 nM). Bractoppin diminishes BRCA1 recruitment to DNA breaks, in turn suppressing damage-induced G2 arrest and assembly of the recombinase, RAD51. Bractoppin preferentially inhibits BRCA1 tBRCT-dependent steps in the DNA damage response .
    Bractoppin
  • HY-131230

    Target Protein Ligand-Linker Conjugates Cancer
    Desmorpholinyl Quizartinib-PEG2-COOH incorporates a ligand for FLT-3, and a PEG-based PROTAC linker. Desmorpholinyl Quizartinib-PEG2-COOH can be used in the synthesis of PROTAC FLT-3 degrader 1 (HY-114323). PROTAC FLT-3 degrader 1 is a PROTAC FLT-3 internal tandem duplication (ITD) degrader with an IC50 0.6 nM .
    Desmorpholinyl Quizartinib-PEG2-COOH
  • HY-144709

    FLT3 Cancer
    FLT3/ITD-IN-1 (Compound 1) is a potent FLT3 internal tandem duplications (FLT3-ITD) inhibitor with IC50 values of 38.2 nM and 144.1 nM against FLT3 and FLT3-ITD, respectively. FLT3/ITD-IN-1 displays excellent antiproliferative activities against acute myeloid leukemia cell lines .
    FLT3/ITD-IN-1
  • HY-144710

    FLT3 Cancer
    FLT3/ITD-IN-2 (Compound 17) is a potent FLT3 internal tandem duplications (FLT3-ITD) inhibitor with IC50 values of 0.3, 0.4 and 1.0 nM against FLT3 D835Y, FLT3 and FLT3-ITD, respectively. FLT3/ITD-IN-2 potently inhibits the phosphorylation of FLT3 and displays excellent antiproliferative activities against acute myeloid leukemia cell lines .
    FLT3/ITD-IN-2
  • HY-144711

    FLT3 Cancer
    FLT3/ITD-IN-3 (Compound 19) is a potent FLT3 internal tandem duplications (FLT3-ITD) inhibitor with IC50 values of 0.3, 0.4 and 0.9 nM against FLT3 D835Y, FLT3 and FLT3-ITD, respectively. FLT3/ITD-IN-3 potently inhibits the phosphorylation of FLT3 and displays excellent antiproliferative activities against acute myeloid leukemia cell lines .
    FLT3/ITD-IN-3
  • HY-145015

    HM43239

    FLT3 Apoptosis Cancer
    Tuspetinib (HM43239) is an orally active and selective FLT3 inhibitor with IC50s of 1.1 nM, 1.8 nM and 1.0 nM for FLT3 WT, FLT3 internal tandem duplication (ITD) and FLT3 D835Y kinases, respectively. Tuspetinib inhibits the kinase activity of FLT3 as a reversible type I inhibitor and modulates p-STAT5, p-ERK, SYK, JAK1/2, and TAK1. Tuspetinib inhibits the proliferation and induces the apoptosis of leukemic cells .
    Tuspetinib
  • HY-145015A

    HM43239 hydrate

    FLT3 Apoptosis Cancer
    Tuspetinib (HM43239) hydrate is an orally active and selective FLT3 inhibitor with IC50s of 1.1 nM, 1.8 nM and 1.0 nM for FLT3 WT, FLT3 internal tandem duplication (ITD) and FLT3 D835Y kinases, respectively. Tuspetinib hydrate inhibits the kinase activity of FLT3 as a reversible type I inhibitor and modulates p-STAT5, p-ERK, SYK, JAK1/2, and TAK1. Tuspetinib hydrate inhibits the proliferation and induces the apoptosis of leukemic cells .
    Tuspetinib hydrate
  • HY-111249

    FLT3 Cancer
    TTT 3002 is a potent and orally active FLT3 inhibitor. TTT 3002 potently inhibits FLT3 phosphorylation by activating mutations at residue D835, with an IC50 of 0.2 nM. TTT 3002 can be used for AML (acute myeloid leukemia) research .
    TTT 3002
  • HY-136490

    Galactosylsphingosine

    PKC Neurological Disease Cancer
    Psychosine (Galactosylsphingosine), a substrate of the galactocerebrosidase (GALC) enzyme, is a potential biomarker for Krabbe disease . Psychosine is a highly cytotoxic lipid, capable of inducing cell death in a wide variety of cell types including, most relevantly to globoid cell leukodystrophy (GLD), oligodendrocytes. Psychosine causes cell death at least in part via apoptosis. Psychosine also is an inhibitor of PKC .
    Psychosine

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: